Psychiatry Research
Volume 109, Issue 1 , Pages 27-35 , 31 January 2002

Cannabis use correlates with schizotypal personality traits in healthy students

  • Patrick Dumas

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • ,
  • Mohamed Saoud

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • INSERM U534, Hôpital Neurologique, F-69003 Lyon, France
    • ,
  • Sébastien Bouafia

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • ,
  • Christel Gutknecht

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • ,
  • René Ecochard

      Affiliations

    • Unité de Biostatistiques (D.I.M. H.C.L.), 162 Avenue Lacassagne, F-69424 Lyon Cedex, France
    • ,
  • Jean Daléry

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • ,
  • Thierry Rochet

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • ,
  • Thierry d'Amato

      Affiliations

    • EA 3092, Université Lyon I, 95 Boulevard Pinel, F-69677 Bron Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-4-3791-5248; fax: +33-4-3791-5102

Received 3 July 2001 ,Revised 16 July 2001 ,Accepted 13 August 2001.

References 

  1. Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica. 1993;88:21–24
  2. Ameri A. The effects of cannabinoids on the brain. Progress in Neurobiology. 1999;58:315–348
  3. American Psychiatric Association . DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  4. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1987;ii:1483–1485
  5. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm Country. Acta Psychiatrica Scandinavica. 1989;79:505–510
  6. Assouly-Besse F, Dollfus S, Petit M. Traduction française des questionnaires d'anhédonie sociale et physique de Chapman: validation de la traduction française à partir de témoins et de patients schizophrènes. Encephale. 1995;21:273–284
  7. Beck AT, Beamesderfer A. Assessment of depression: the Depression Inventory. In:  Pichot P editors. Psychological Measurements in Psychopharmacology. Modern Problems in Pharmacopsychiatry. 7:1974;p. 151–159
  8. Bornstein RF, Klein DN, Mallon JC, Slater JF. Schizotypal personality disorder in an outpatient population: incidence and clinical characteristics. Journal of Clinical Psychology. 1988;44:322–325
  9. Bourque, B., Beaudrette, C., 1982. French version of the Beck 13, Unpublished translation.
  10. Braunstein-Bercovitz H. Is the attentional dysfunction in schizotypy related to anxiety?. Schizophrenia Research. 2000;46:255–267
  11. Breakey W, Goodel H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. Psychological Medicine. 1974;4:255–261
  12. Caspari D. Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neurosciences. 1999;249:45–49
  13. Chapman LJ, Chapman JP. Revised Physical Anhedonia Scale. Madison, WI: Unpublished scale. University of Wisconsin; 1978;
  14. Chapman LJ, Chapman JP, Kwapil TR, Eckblad ML, Zinser MC. Putatively psychosis prone individuals ten years on. Journal of Abnormal Psychology. 1994;103:171–183
  15. Chapman LJ, Chapman JP, Raulin ML. Body-image aberration in schizophrenia. Journal of Abnormal Psychology. 1978;87:399–407
  16. Claridge GS, Broks P. Schizotypy and hemisphere function: I. Theoretical considerations and the measurement of schizotypy. Personality and Individual Differences. 1984;5:633–648
  17. Compton WM, Cottler LB, Ben Abdallah A, Phelps DL, Spitznagel EL, Horton JC. Substance dependence and other psychiatric disorders among drug dependent subjects: race and gender correlates. American Journal of Addiction. 2000;9:113–125
  18. Dumas P, Daléry J, Saoud M, d'Amato T. Traductions et adaptations françaises des questionnaires d'idéation magique (MIS; Eckblad and Chapman, 1983) et d'aberrations perceptives (PAS; Chapman et coll. 1978). Encephale. 1999;25:422–428
  19. Dumas P, Rosenfeld F, Saoud M, Daléry J, d'Amato T. Traduction et adaptation française du questionnaire de personnalité schizotypique de Raine (SPQ). Encephale. 1999;25:315–322
  20. Eckblad ML, Chapman LJ. Magical Ideation as an indicator of schizotypy. Journal of Consulting and Clinical Psychology. 1983;51:215–225
  21. Fyer AJ, Endicott J, Mannuzza S, Klein DF. Schedule for Affective Disorders and Schizophrenia — Lifetime Anxiety Version. New York: New York State Psychiatric Institute; 1985;
  22. Gibbons RD. Mixed-effects models for mental health services research. Health Services and Outcomes Research Methodology. 2000;1:91–129
  23. Halikas J, Goodwin D, Guze S. Marijuana use and psychiatric illness. Archives of General Psychiatry. 1972;27:162–165
  24. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Australian and New Zealand Journal of Psychiatry. 2000;34:26–34
  25. Kwapil TRA. Longitudinal study of drug and alcohol use by psychosis-prone and impulsive-nonconforming individuals. Journal of Abnormal Psychology. 1996;105:114–123
  26. Kwapil TR, Miller MB, Zinser MC, Chapman JP, Chapman LJ. Magical ideation and social anhedonia as predictor of psychosis proneness: a partial replication. Journal of Abnormal Psychology. 1997;106:491–495
  27. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665–1669
  28. Lenzenweger MF, Loranger AW. Psychosis proneness and clinical psychopathology: examination of the correlates of schizotypy. Journal of Abnormal Psychology. 1989;98:3–8
  29. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry. 1994;51:273–279
  30. Martin GW, Wilkinson DA, Kapur BM. Validation of self-reported cannabis use by urine analysis. Addiction Behavior. 1988;13:147–150
  31. Miller LS, Burns SA. Gender differences in schizotypic features in a large sample of young adults. Journal of Nervous and Mental Disease. 1995;183:657–661
  32. Mishlove M, Chapman LJ. Social anhedonia in the prediction of psychosis proneness. Journal of Abnormal Psychology. 1985;94:384–396
  33. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine. 1986;16:515–520
  34. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scandinavica. 1992;85:127–130
  35. Pickard M, Bates L, Dorian M, Greig H, Saint D. Alcohol and drug use in second-year medical students at the University of Leeds. Medical Education. 2000;34:86–87
  36. Poulton RG, Brooke M, Moffitt TE, Stanton WR, Silva PA. Prevalence and correlates of cannabis use and dependence in young New Zealanders. New Zealand Medical Journal. 1997;110:68–70
  37. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin. 1991;17:555–564
  38. Raine A. Sex differences in schizotypal personality in a nonclinical population. Journal of Abnormal Psychology. 1992;101:361–364
  39. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93:837–846
  40. Schneider U, Leweke FM, Mueller-Vahl KR, Emrich HM. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?. Pharmacopsychiatry. 1998;31(Suppl. 2):110–113
  41. Schweitzer MB, Paulhan I. Manual pour l'Inventaire d'Anxiété Trait-Etat (Forme Y). Bordeaux, France: Laboratoire de Psychologie de la Santé, Université de Bordeaux II; 1990;
  42. Spielberger CD. Manual for the State-Trait Anxiety Inventory (Form Y) (‘Self-Evaluation Questionnaire’). Palo Alto, CA: Consulting Psychologists Press; 1983;
  43. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Archives of General Psychiatry. 1972;27:133–136
  44. Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence. 1996;42:201–207
  45. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association?. British Journal of Psychiatry. 1990;157:25–33
  46. Troisi A, Pasini A, Saracco M, Spalletta G. Psychiatric symptoms in male cannabis users not using other illicit drugs. Addiction. 1998;93:487–492
  47. VanLeuwen D, Barnes M, Pase M. Generalizability theory: a unified approach to assessing the dependability (reliability) of measurements in the health sciences. Journal of Outcome Measurement. 1998;2:302–325
  48. Williams JH, Wellman NA, Rawlins JNP. Cannabis use correlates with schizotypy in healthy people. Addiction. 1996;91:869–877

PII: S0165-1781(01)00358-4

Psychiatry Research
Volume 109, Issue 1 , Pages 27-35 , 31 January 2002

Article Tools